Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial.
- EClinicalMedicine, Oct 2023, 64 102140 | https://doi.org/10.1016/j.eclinm.2023.102140